

Resource Summary Report

Generated by SPARC SAWG on Aug 11, 2026

Purified anti-mouse CD28

RRID:AB_312867

Type: Antibody

Proper Citation

BioLegend Cat# 102102, RRID:AB_312867

Antibody Information

URL: http://antibodyregistry.org/AB_312867

Proper Citation: BioLegend Cat# 102102, RRID:AB_312867

Target Antigen: CD28

Host Organism: syrian hamster

Clonality: monoclonal

Comments: Applications: FC, IP, IHC-F, Costim, Block

Antibody Name: Purified anti-mouse CD28

Description: This monoclonal targets CD28

Target Organism: mouse

Clone ID: Clone 37.51

Antibody ID: AB_312867

Vendor: BioLegend

Catalog Number: 102102

Alternative Catalog Numbers: 102101

Record Creation Time: 20250819T222446+0000

Record Last Update: 20250820T020635+0000

Ratings and Alerts

No rating or validation information has been found for Purified anti-mouse CD28.

No alerts have been found for Purified anti-mouse CD28.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 42 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Tsuruta A, et al. (2026) C-X-C chemokine receptor CXCR4 mediates diurnal changes in the aggregation and dispersion of CD8+ T cells within the tumor microenvironment. International journal of cancer, 158(6), 1740.

Magno JC, et al. (2026) Engineering T Cells with a Tumor-Reactive Chimeric T-cell Receptor Reduces Exhaustion and Promotes Persistence to Elicit Enhanced Antitumor Responses. Cancer research, 86(11), 2688.

Wang Y, et al. (2026) Tuning the sensitivity of mechanosensory receptors through histidine scanning. Cell, 189(6), 1680.

Navarro Negredo P, et al. (2026) Targeting immune cells in the aged brain reveals that engineered cytokine IL-10 enhances neurogenesis and improves cognition. Immunity, 59(2), 458.

Wang Y, et al. (2026) A blood-brain barrier-like vascular gate limits immunotherapy efficacy in neuroendocrine cancers. Cell, 189(13), 3922.

Menezes-Silva L, et al. (2026) Hormonal rewiring of immunity during dietary restriction ensures host defense and systemic glucose conservation. Immunity, 59(3), 700.

Zhou S, et al. (2026) Vascular normalization by erianin unleashes CAR-T immunotherapy in glioblastoma. Angiogenesis, 29(2), 18.

Kirschstein E, et al. (2026) Myofibroblast programming blocks differentiation of TLS-organizing fibroblastic reticular cells in pancreatic cancer. Cancer cell, 44(5), 1080.

Wang L, et al. (2026) The circadian gene Dec2 promotes pancreatic cancer progression and dormancy through immune evasion. Developmental cell, 61(6), 1208.

Gu Y, et al. (2026) Targeting cholesterol esterification sensitizes liver cancer to CD8+ T cell attack by impairing metabolic and redox resilience. Immunity, 59(7), 1948.

Wang Z, et al. (2025) Tumor microenvironment-associated oxidative stress impairs SIRT1 secretion to suppress anti-tumor immune response. Cell reports, 44(5), 115679.

Wang C, et al. (2025) The glycolytic reaction PGAM restrains Th17 pathogenicity and Th17-dependent autoimmunity. *Cell reports*, 44(6), 115799.

Fan Q, et al. (2025) Hepatic Lamp2a deficiency promotes inflammation of murine autoimmune cholangitis via affecting bile acid metabolism. *iScience*, 28(2), 111804.

Cheng JN, et al. (2025) Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclasts. *Cancer cell*, 43(6), 1093.

Zhang FQ, et al. (2025) Zeaxanthin augments CD8⁺ effector T cell function and immunotherapy efficacy. *Cell reports. Medicine*, 6(9), 102324.

Shi Y, et al. (2025) Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors. *EMBO reports*, 26(2), 521.

Even Z, et al. (2024) The amalgam of naive CD4⁺ T cell transcriptional states is reconfigured by helminth infection to dampen the amplitude of the immune response. *Immunity*, 57(8), 1893.

Xu Z, et al. (2024) Nuclear HMGB1 is critical for CD8 T cell IFN- γ production and anti-tumor immunity. *Cell reports*, 43(8), 114591.

Zhou S, et al. (2024) CD97 maintains tumorigenicity of glioblastoma stem cells via mTORC2 signaling and is targeted by CAR Th9 cells. *Cell reports. Medicine*, 5(12), 101844.

Buquicchio FA, et al. (2024) Distinct epigenomic landscapes underlie tissue-specific memory T cell differentiation. *Immunity*, 57(9), 2202.